Warfarin Dosing for Atrial Fibrillation
For patients with atrial fibrillation, target an INR of 2.0-3.0 (target 2.5), starting with 5 mg daily for most patients, but reduce to 2-4 mg daily for patients over 75 years old or weighing less than 60 kg. 1, 2, 3
Target INR Range
The therapeutic target for warfarin in atrial fibrillation is consistently an INR of 2.0-3.0 across all major guidelines 1, 2, 3. This range provides optimal stroke prevention while minimizing bleeding risk. Research confirms that lower intensity anticoagulation (INR ≤1.6) results in significantly more thromboembolic events without reducing major bleeding 4.
Starting Dose
Standard Adult Dose
- Start with 5 mg daily for most patients 3, 5
- Avoid loading doses, which can cause excessive INR elevation 5
Elderly Patients (≥75 years)
- Start with 2-4 mg daily 3, 5
- The FDA label specifically warns that patients ≥60 years exhibit greater PT/INR response and require lower initiation doses 3
- Age-adjusted protocols achieve stable therapeutic INR more rapidly and with fewer supratherapeutic INRs compared to standard protocols 6
Low Body Weight (<60 kg)
- Start with 2-4 mg daily 3
- Lower doses are necessary due to increased drug exposure in smaller patients
High Bleeding Risk
- Consider targeting INR 1.6-2.5 (target 2.0) for patients >75 years at high bleeding risk 7, 2
- However, recognize this provides approximately 80% of the efficacy of standard-intensity anticoagulation 2
Monitoring Schedule
Initial phase (first week):
- Check INR daily until stable 3
- The INR will not rise appreciably in the first 24 hours with appropriate starting doses 5
Titration phase:
Maintenance phase:
- Check monthly when stable 3
- Can extend to every 4-6 weeks in patients with consistently stable INRs 5
Dose Adjustments
When adjusting warfarin doses:
- Change the total weekly dose by 5-20% rather than making large daily dose changes 5
- Do not adjust for a single slightly out-of-range INR 5
- Most patients achieve stable anticoagulation with 2-5 mg daily (approximately 80% of elderly patients) 8
Special Populations
Patients with End-Stage Renal Disease
- Warfarin may be reasonable with CrCl <15 mL/min or on hemodialysis, targeting INR 2.0-3.0 1
- However, evidence shows warfarin in ESRD patients with AF provides no reduction in ischemic stroke, increases hemorrhagic stroke risk, and does not reduce mortality 9
- Direct oral anticoagulants (dabigatran, rivaroxaban) are not recommended in ESRD due to lack of evidence 1
Patients on Concurrent Antiplatelet Therapy
- Target INR 2.0-2.5 when combining warfarin with aspirin and/or P2Y12 inhibitors 10, 11
- This lower range is particularly important in elderly patients and those with bleeding risk factors 10, 11
Common Pitfalls
Avoid loading doses: They cause excessive INR elevation without achieving therapeutic anticoagulation faster 5
Don't use standard 5 mg starting dose in elderly patients: Age-adjusted protocols (2-4 mg) are superior and safer 6
Don't target lower INR ranges routinely: While INR 1.6-2.5 may reduce bleeding in very elderly patients, it provides incomplete stroke protection 2, 4
Monitor more frequently during illness or medication changes: Elderly patients experience more INR fluctuations 12
Reassess bleeding and stroke risk periodically: Risk profiles change over time, particularly with advancing age 1, 13